RESUMEN
OBJECTIVE: Our aim was to evaluate the relationship between esophageal dysmotility and lung disease by correlating the results of Echocardiogram and Pulmonary Function Test (PFT) with Esophageal Transit Study (ETT). METHODS: Charts of Systemic Sclerosis (SSc) patients fulfilling 2013 ACR/EULAR classification criteria seen in Rheumatology clinics were reviewed and their demographics, ETT result, PFT, and echocardiogram data were collected at baseline, years 1, 3, 5, and 10. Patients were divided based on their ETT status and were compared with respect to each variable using a two-sided two-sample t test for continuous variables and a Fisher's exact test for categorical variables. RESULTS: 130 patients were identified with either limited cutaneous SSc (109) or diffuse cutaneous SSc (21) with a mean age of 52.65 years. The mean DLCO was statistically worse in abnormal ETT patients [p value = 0.0004] as were the progression rates per year for DLCO at - 2.25 (p value = 0.019). Progression rate of FVC per year was statistically significant in the abnormal ETT group, although the mean value was not. The number of patients with abnormal PASP was not statistically different between the two groups (p values 0.104, 0.178, 0.653 at baseline, years 3 and 5, respectively). CONCLUSION: The presence of esophageal dysmotility was associated with increased pulmonary involvement in the form of abnormal DLCO with worsening progression rates per year. There was no statistically significant difference in PASP and FVC between the two groups; however, the progression rate for FVC was worse in adjusted models.
Asunto(s)
Trastornos de la Motilidad Esofágica/etiología , Enfermedades Pulmonares Intersticiales/etiología , Esclerodermia Sistémica/complicaciones , Adulto , Anciano , Progresión de la Enfermedad , Ecocardiografía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pruebas de Función Respiratoria , Estudios Retrospectivos , Esclerodermia Sistémica/fisiopatologíaRESUMEN
The aim of this paper is to review and discuss the background, common manifestations, differential diagnosis, and current treatment practices of reactive arthritis. The focus will be on the choice of therapy in patients with poor prognostic factors. A PubMed search was performed in March 2020 on reactive arthritis and revealed 137 articles. Fourteen case reports and four large-scale studies that are pertinent for discussion in terms of treatment of reactive arthritis over the past five years are reported along with poor prognostic markers. The first choice of therapy regardless of the number of poor prognostic markers is non-steroidal anti-inflammatory drugs (NSAIDs). The second choice of therapy appeared to be glucocorticoids in the oral as well as intra-articular forms. No correlation was detected between the need for systemic steroids and the number of poor prognostic factors present. The third choice of therapy appears to be disease-modifying anti-rheumatic drugs (DMARDs) (such as sulfasalazine) and their increasing use can be demonstrated over time. Novel therapies such as adalimumab have also been shown to be used and this shows a strong correlation with an increased number of poor prognostic factors. Reporting of these case reports and review of literature contribute to knowing more about reactive arthritis and help keep us up to date with newer therapies available when patients do not respond to conventional therapy. It was notable that the increased number of poor prognostic factors and non-responders have shown increased use of tumor necrosis factor inhibitors (TNFI) such as adalimumab.
Asunto(s)
Enfermedades Autoinmunes/tratamiento farmacológico , Productos Biológicos/uso terapéutico , Infecciones por Coronavirus/epidemiología , Cuidados Críticos/estadística & datos numéricos , Hospitalización/estadística & datos numéricos , Inmunosupresores/uso terapéutico , Neumonía Viral/epidemiología , Adulto , Anciano , Artritis Juvenil/tratamiento farmacológico , Artritis Juvenil/epidemiología , Artritis Psoriásica/tratamiento farmacológico , Artritis Psoriásica/epidemiología , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/epidemiología , Enfermedades Autoinmunes/epidemiología , Betacoronavirus , COVID-19 , Colitis Ulcerosa/tratamiento farmacológico , Colitis Ulcerosa/epidemiología , Infecciones por Coronavirus/mortalidad , Infecciones por Coronavirus/terapia , Enfermedad de Crohn/tratamiento farmacológico , Enfermedad de Crohn/epidemiología , Femenino , Humanos , Intubación Intratraqueal/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Mortalidad , Pandemias , Neumonía Viral/mortalidad , Neumonía Viral/terapia , SARS-CoV-2 , Espondilitis Anquilosante/tratamiento farmacológico , Espondilitis Anquilosante/epidemiología , Inhibidores del Factor de Necrosis Tumoral/uso terapéuticoRESUMEN
Human immunodeficiency virus (HIV) infection can result in several autoimmune illnesses, including psoriasis, psoriatic arthritis (PsA), and polyarteritis nodosa (PAN). We describe a patient who presented with PsA refractory to both synthetic and biologic disease-modifying antirheumatic drugs (DMARDs), who then developed PAN while on antitumor necrosis factor (TNF) therapy. The onset ofvasculitic disease led to the discovery of the HIV infection, and manifestations of both PsA and PAN remitted with the introduction of highly active antiretroviral therapy. To our knowledge, this is the first casewhere both PsA and PAN developed in an HIV-positive patient. Our review focuses on the pathogenesis, presentation, and treatment of HIV related psoriasis, PsA, and PAN. This unusual case underscores the need to remain vigilant for underlying HIV infection in immunosuppressed patients, and serves as a reminder ofthe unusual autoimmune manifestations the virus can provoke.
Asunto(s)
Terapia Antirretroviral Altamente Activa , Antirreumáticos/uso terapéutico , Artritis Psoriásica/complicaciones , Infecciones por VIH/complicaciones , Huésped Inmunocomprometido , Poliarteritis Nudosa/complicaciones , Adulto , Terapia Antirretroviral Altamente Activa/métodos , Artritis Psoriásica/diagnóstico , Artritis Psoriásica/tratamiento farmacológico , Quimioterapia Combinada , Infecciones por VIH/diagnóstico , Infecciones por VIH/tratamiento farmacológico , Humanos , Masculino , Poliarteritis Nudosa/diagnóstico , Poliarteritis Nudosa/tratamiento farmacológico , Pronóstico , Resultado del TratamientoRESUMEN
Giant cell arteritis (GCA) is a chronic vasculitis, characterized by inflammation of large- and medium-sized arteries, primarily affecting the external carotid artery and its branches, especially the superficial temporal artery. We describe a series of three cases of "extracranial GCA" involving the aorta and its branches in the absence of classical cranial arteritis symptoms at the onset. Because of the paucity of disease-specific manifestations and its variability, extracranial GCA can be an overlooked clinical entity. Our clinical series illustrates that early recognition can be challenging but critical in preventing potentially devastating complications.
Asunto(s)
Enfermedades de la Aorta/diagnóstico , Arteritis de Células Gigantes/diagnóstico , Anciano de 80 o más Años , Angiografía por Tomografía Computarizada , Femenino , Humanos , Angiografía por Resonancia Magnética , Masculino , Persona de Mediana Edad , Dolor/etiologíaRESUMEN
This study aims to compare the severity and outcomes of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) between Hispanics and Caucasians living in the same geographical area. All patients diagnosed with AAV at two academic institutions in Chicago from January 2006 to December 2012 were retrospectively and prospectively identified. Disease activity was measured with the Birmingham Vasculitis Activity Score (BVAS), and disease damage was measured with the Vasculitis Damage Index (VDI). Student's t test and chi-square tests were employed; p ≤ 0.05 was considered significant. Seventy patients with AAV were identified; 15 patients were excluded. Fifty-five patients were included in the study: 23 Hispanics and 32 Caucasians, 35 patients with granulomatosis with polyangiitis (Wegener's), 12 with microscopic polyangiitis, 7 with eosinophilic granulomatosis with polyangiitis, and 1 with renal-limited vasculitis. Compared to Caucasians, Hispanics had a higher BVAS at presentation (16.3 ± 7.6 versus 10.7 ± 7.5, p = 0.006), a higher VDI at presentation (2.90 ± 1.50 versus 2.06 ± 1.30, p = 0.030), and a cumulative VDI (3.90 ± 1.70 versus 2.50 ± 1.90, p = 0.010). Renal involvement was more common among Hispanics (85 % of Hispanics versus 48 % of Caucasians, p = 0.01). Seventy percent of Hispanics had acute renal failure (mean creatinine = 3.37 ± 4.4 mg/dl) of whom seven (50 %) required dialysis, versus 25 % of Caucasians (mean creatinine = 1.78 ± 1.57 mg/dl, p = 0.03) and only two requiring dialysis. Compared to Caucasians, Hispanics with AAV present with more severe disease and higher damage indices. Larger studies are required to confirm these findings and delineate the respective roles of environment and genetics in the pathogenesis of the disease.
Asunto(s)
Lesión Renal Aguda/etnología , Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/etnología , Hispánicos o Latinos , Lesión Renal Aguda/sangre , Lesión Renal Aguda/etiología , Lesión Renal Aguda/terapia , Adulto , Anciano , Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/complicaciones , Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/fisiopatología , Chicago , Síndrome de Churg-Strauss/complicaciones , Síndrome de Churg-Strauss/etnología , Síndrome de Churg-Strauss/fisiopatología , Creatinina/sangre , Femenino , Granulomatosis con Poliangitis/complicaciones , Granulomatosis con Poliangitis/etnología , Granulomatosis con Poliangitis/fisiopatología , Humanos , Masculino , Poliangitis Microscópica/complicaciones , Poliangitis Microscópica/etnología , Poliangitis Microscópica/fisiopatología , Persona de Mediana Edad , Diálisis Renal , Índice de Severidad de la Enfermedad , Población BlancaRESUMEN
Vasculitis causing palpable purpura, nephropathy, and hematologic abnormalities is a well-known entity. However, sometimes, vasculitis may not be the primary cause but is part of a systemic disease. Literature suggests that infections like HIV can induce nephropathy and antineutrophilic cytoplasmic antibody-positive vasculitis, which is different from the well-known entity of "antineutrophilic cytoplasmic antibody-associated vasculitis." We present a 46-year-old female patient with a history of intravenous drug abuse who reported with a rash, swelling, and palpable purpura of the lower extremities. Peripheral smear showed no evidence of disseminated intravascular coagulation or thrombotic thrombocytopenic purpura; metabolic profile showed acute kidney injury. She was found to be HIV- and hepatitis C-positive. Immunologic workup was positive for both MPO and PR3 antineutrophilic cytoplasmic antibodies and negative for cryoglobulins; complement levels were low. Skin biopsy showed leukocytoclastic vasculitis but kidney biopsy was negative for any immunologic involvement; it showed only glomerulosclerosis. Thus, it was thought that nephropathy and vasculitis, in this case, are two distinct pathologic processes, both induced by infection (HIV and/or hepatitis C). The patient responded to low-dose steroid therapy. She was later started on the definitive therapy, the highly active antiretroviral therapy regimen. This case illustrates the fact that low-dose steroids can still be a good alternative in acute situations in patients at risk from immunosuppression.